92403
document
Pelvic lymphocysts following retroperitoneal lymphadenectomy : retroperitoneal partial " no-closure " for ovarian and endometrial cancers . BACKGROUND AND OBJECTIVES Pelvic lymphocysts have been reported mainly following pelvic lymphadenectomy for cervical cancer . We attempted to assess whether retroperitoneal partial " no-closure " reduces the incidence of lymphocyst formation following retroperitoneal lymphadenectomy . METHODS Sixty-one patients with ovarian cancer or endometrial cancer who underwent retroperitoneal lymph node resection were assigned at random to a retroperitoneal partial " no-closure " group or a " closure " group . The incidence of lymphocysts in the two groups as determined using ultrasonography was compared . RESULTS Lymphocysts appeared in 23/61 patients ( 38 % ) in total . In the " closure " group , the incidence was 52 % ( 16/31 ) , but in the " no-closure " group it was only 23 % ( 7/30 ) ; the incidence in the " no-closure " group was significantly lower ( P < 0.05 ) . The incidence of postoperative fever was 17 % ( 5/30 ) in the " no-closure " group , which was lower than that in the " closure " group ( 42 % , 13/31 ) , but not significantly so ( P < 0.1 ) . No patients in the " no-closure " group required surgical procedures such as needle aspiration or cyst drainage . CONCLUSIONS Retroperitoneal partial " no-closure " appears to be a useful procedure for reducing the incidence of pelvic lymphocysts associated with retroperitoneal lymphadenectomy .
92404
Intervention_Physical
retroperitoneal partial " no-closure "
92405
Intervention_Physical
retroperitoneal partial " no-closure "
92406
Intervention_Physical
retroperitoneal partial " no-closure " group
92407
Intervention_Surgical
a "
92408
Intervention_Physical
closure " group
92409
Intervention_Physical
Retroperitoneal partial " no-closure
92410
Outcome_Physical
lymphocyst formation
92411
Outcome_Physical
lymphocysts
92412
Outcome_Physical
Lymphocysts
92413
Outcome_Adverse-effects
postoperative fever
92414
Outcome_Physical
pelvic lymphocysts
92415
Participant_Sample-size
Sixty-one
92416
Participant_Condition
ovarian cancer
92417
Participant_Condition
endometrial cancer
92418
Participant_Condition
retroperitoneal lymph node resection